Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00349245 · ClinicalTrials.gov registry record · Phase 4
Dexmedetomidine vs. Remifentanil for Sedation During AFI
A Phase 4 study of Intubation, Endotracheal, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00349245: Completed Phase 4 study of Intubation, Endotracheal, sponsored by The University of Texas Health Science Center, Houston.
NCT00349245 is a Phase 4 study of Intubation, Endotracheal that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00349245, a Phase 4 study of Intubation, Endotracheal, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to determine the efficacy and safety of Dexmedetomidine, a selective alpha-2 adrenoceptor agonist, which has recently gained increased popularity for ICU and intraoperative sedation as a sedative during awake fiberoptic intubation, as compared to Remifentanil. The hypothesis is that Dexmedetomidine will provide at least equal if not better conditions (sedation and analgesia) required for awake fiberoptic intubation (Ramsay Sedation Scale 3) with less respiratory and cardiovascular adverse effects, as well as less recall than Remifentanil.
Conditions Studied
Interventions
- DRUG Dexmedetomidine
- DRUG Remifentanil
Study Locations (1)
Texas
- Memorial Hermann Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
What the finished NCT00349245 record still lists
NCT00349245 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Intubation, Endotracheal appearing as the primary indexed condition, and to 2 interventions - of which Dexmedetomidine is the first listed.
NCT00349245 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00349245 about?
NCT00349245 is a clinical study titled "Dexmedetomidine vs. Remifentanil for Sedation During AFI". The objective of this study is to determine the efficacy and safety of Dexmedetomidine, a selective alpha-2 adrenoceptor agonist, which has recently gained increased popularity for ICU and intraoperative sedation as a sedative during awake fiberoptic intubation, as compared to Remifentanil. The hyp...
What is the current status of trial NCT00349245?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2006-06. Estimated completion is 2007-08.
What conditions does trial NCT00349245 study?
This clinical trial studies the following conditions: Intubation, Endotracheal.
What interventions are being tested in trial NCT00349245?
The interventions under investigation include: Dexmedetomidine (DRUG), Remifentanil (DRUG).
Who is sponsoring clinical trial NCT00349245?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00349245 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intubation, Endotracheal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00349245's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia